EverSource Wealth Advisors’s Cytek Biosciences CTKB Stock Holding History

EverSource Wealth Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.96K	Buy	1,821 +242	+15%	+$1.14K	﹤0.01%	3040
2025 Q4	$7.97K	Sell	1,579 -206	-12%	-$957	﹤0.01%	2916
2025 Q3	$6.19K	Buy	1,785 +5	+0.3%	+$19	﹤0.01%	3058
2025 Q2	$6.05K	Buy	1,780 +1,246	+233%	+$4.15K	﹤0.01%	3069
2025 Q1	$2.14K	Buy	534 +449	+528%	+$2.33K	﹤0.01%	2899
2024 Q4	$552	Buy	+85	New	+$506	﹤0.01%	3152
2024 Q3	–	Sell	-158	Closed	-$1.06K	–	3051
2024 Q2	$1.06K	Hold	158	–	–	﹤0.01%	2728
2024 Q1	$950	Buy	158 +26	+20%	+$206	﹤0.01%	2602
2023 Q4	$1.2K	Buy	+132	New	+$831	﹤0.01%	2338
2023 Q3	–	Sell	-69	Closed	-$589	–	2534
2023 Q2	$589	Buy	+69	New	+$619	﹤0.01%	2317

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EverSource Wealth Advisors's CTKB Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Cytek Biosciences (CTKB) stake by 15% in Q1 2026, buying an estimated $1.14K and bringing the position to 1,821 shares worth $7.96K. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

EverSource Wealth Advisors first reported a position in CTKB in Q2 2023 and has held it in 10 quarters since. The position peaked at $7.97K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

EverSource Wealth Advisors held 1,821 shares of Cytek Biosciences worth $7.96K as of Q1 2026.
EverSource Wealth Advisors bought 242 Cytek Biosciences shares in Q1 2026, an estimated $1.14K.
Cytek Biosciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3040 holding.
EverSource Wealth Advisors first reported a position in Cytek Biosciences in Q2 2023 and has held it in 10 quarters since.
EverSource Wealth Advisors's Cytek Biosciences position peaked at $7.97K in Q4 2025.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.